ContraVir Pharmaceuticals Receives Positive FDA Response to CRV431 Pre-IND Package for NASH
20 juin 2019 16h30 HE
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 20, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals, Inc. Announces Pricing of $15.6 Million Public Offering
18 juin 2019 08h45 HE
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 18, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (“ContraVir,” the “Company,” “we,” “our” or “us”) (NASDAQ:CTRV), a biopharmaceutical company focused on the...
Compelling Positive Results Reported from Human Liver Experiments with ContraVir Pharmaceuticals’ NASH Drug Candidate
17 juin 2019 08h00 HE
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 17, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals Announces Publication of CRV431 Data from Experimental Model of Hepatitis B
11 juin 2019 08h30 HE
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 11, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibrosis
06 juin 2019 08h00 HE
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 06, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split
31 mai 2019 08h00 HE
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., May 31, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Decision
06 mai 2019 08h00 HE
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., May 06, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals to Present at the 2019 ThinkEquity Conference
29 avr. 2019 08h30 HE
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., April 29, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals, Inc. Announces Pricing of $2.14 Million Public Offering
25 avr. 2019 09h02 HE
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., April 25, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (“ContraVir,” the “Company,” “we,” “our” or “us”) (NASDAQ:CTRV), a biopharmaceutical company focused on the...
ContraVir Pharmaceuticals to Present CRV431 Phase 1 Data at the International Liver Congress™
11 avr. 2019 08h00 HE
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., April 11, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...